Chronic open-angle glaucoma. Review for primary care physicians

Canadian Family Physician

Volumn 51, Issue SEPT., 2005, Pages 1229-1237

  Adatia, Feisal A ^b   Damji, Karim F ^a  

^a UNIVERSITY OF OTTAWA EYE INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHAGAN P; ANTIGLAUCOMA AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBACHOL; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; COMBIGAN; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL MALEATE; LEVOBUNOLOL; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA; STEROID; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST;

ANAPHYLAXIS; ANGINA PECTORIS; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ASTHMA; ASTHMATIC STATE; AWARENESS; BLOOD DYSCRASIA; BODY WEIGHT DISORDER; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG HYPERSENSITIVITY; EARLY DIAGNOSIS; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; EYE DISEASE; FAMILY HISTORY; FATIGUE; GASTROINTESTINAL DISEASE; GENERAL PRACTITIONER; GRANULOCYTOPENIA; HEADACHE; HEART ARRHYTHMIA; HEART BLOCK; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; HYPOTHYROIDISM; IATROGENIC DISEASE; INSOMNIA; INTRAOCULAR HYPERTENSION; KIDNEY FAILURE; LUNG EDEMA; MALAISE; MEDICAL EXPERT; MEDICAL SPECIALIST; MEDLINE; METABOLIC ACIDOSIS; METABOLIC DISORDER; MUSCLE WEAKNESS; MYALGIA; MYOCARDIAL DISEASE; MYOPIA; NAUSEA; NEGRO; NEPHROLITHIASIS; NEUROMUSCULAR DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN ANGLE GLAUCOMA; OPHTHALMOLOGY; OPTOMETRY; ORTHOSTATIC HYPOTENSION; PATIENT REFERRAL; POLYURIA; PRIMARY MEDICAL CARE; RACE; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SINUS BRADYCARDIA; SKIN MANIFESTATION; SLEEP APNEA SYNDROME; STEVENS JOHNSON SYNDROME; SYNCOPE; TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; VISION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

BLINDNESS; CHRONIC DISEASE; GLAUCOMA, OPEN-ANGLE; HUMANS; MASS SCREENING; RISK FACTORS;

EID: 24944584158     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980;24(Suppl):335-610.
2. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991;266:369-74.
3. Hitchings RA. Ocular surgery for the new millennium: glaucoma in the new millennium. Ophthalmol Clin North Am 1999;12(4):519-31.
4. American Academy of Ophthalmology. Preferred practice pattern: primary angle-closure glaucoma. San Francisco, Calif: American Academy of Ophthalmology; 2000.
5. Lichter PR. Testimony before: Department of Labor, Health, and Human Services, and Related Agencies. 1st U.S. Congress House Committee on Appropriations for 1993. Washington, DC: Government Printing Office; 1992; pt 8A, 1317-30.
6. Johnson CA, Keltner JL. Incidence of visual field loss in 20,000 eyes and its relationship to driving performance. Arch Ophthalmol 1983;101:371-5.
7. Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA, Ritch R, et al. Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol 1997;115:777-84.
8. Jocson VL, Sears ML. Experimental aqueous perfusion in enucleated human eyes. Results after obstruction of Schlemm's canal. Arch Ophthalmol 1971;86(1):65-71.
9. Bill A, Phillips CI. Uveoscleral drainage of aqueous humour in human eyes. Exp Eye Res 1971;12(3):275-81.
10. Periodic health examination, 1995 update: 3. Screening for visual problems among elderly patients. CMAJ 1995;152:1211-22. Available from: http://www.ctfphc.org/. Accessed 2005 May 25.
11. Boivin J, McGregor M, Archer C. Cost effectiveness of screening for primary open-angle glaucoma. J Med Screen 1996;3:154-63.
12. Tuck MW, Crick RP. The cost-effectiveness of various modes of screening for primary open angle glaucoma. Ophthalmic Epidemiol 1997;4(1):3-17.
13. Huang JT, Rhemtulla F, Huang PT. Glaucoma screening by primary care physicians in southern Alberta: patterns, methods and deficiencies. Can J Ophthalmol 2003;38(4):279-84.
14. Schwartz JT. Methodologic differences and measurement of cup-disc ratio: an epidemiologic assessment. Arch Ophthalmol 1976;94:1101-5.
15. Holmin C. Optic disc evaluation versus the visual field in chronic glaucoma. Acta Ophthalmol 1982;60:275-83.
16. Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol 1982;100:135-46.
17. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53.
18. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120(10):1268-79.
19. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20.
20. Damji KF, Behki R, Wang L; Target IOP Workshop participants. Canadian perspectives in glaucoma management: setting target intraocular pressure range. Can J Ophthalmol 2003;38(3):189-97.
21. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey. Arch Ophthalmol 1994;112:69-73.
22. Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javit J, Singh K. Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991;109(8):1090-5.
23. Jampel HD. Target pressure in glaucoma therapy [review]. J Glaucoma 1997;6(2):133-8.
24. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984;102:551-3.
25. Sorensen SJ, Abel SR. Comparison of the ocular beta-blockers [review]. Ann Pharmacother 1996;30(1):43-54.
26. McMahon CD, Shaffer RN, Hoskins HD Jr, Hetherington J Jr. Adverse effects experienced by patients taking timolol. Am J Ophthalmol 1979;88(4):736-8.
27. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology 1980;87(5):447-50.
28. Jones FL Jr, Ekberg NL. Exacerbation of asthma by timolol. N Engl J Med 1979;301(5):270.
29. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986; 102(5):606-11.
30. Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med 1986;104(2):197-9.
31. Howlett SA. Renal failure associated with acetazolamide therapy for glaucoma. South Med 1975;68(4):504-6.
32. Higenbottam T, Ogg CS, Saxton HM. Acute renal failure from the use of acetazolamilde (Diamox). Postgrad Med J 1978;54(628):127-8.
33. Fraunfelder FT, Meyer SM, Bagby GC Jr, Dreis MW. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol 1985;100(1):79-81.
34. Tuulonen A, Airaksinen PJ, Erola E, Forsman E, Friberg K, Kaila M. The Finnish evidence-based guideline for open-angle glaucoma. Acta Ophthalmol Scand 2003;81:3-18.